Overview A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency Status: Recruiting Trial end date: 2022-10-01 Target enrollment: Participant gender: Summary This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency. Phase: Phase 2 Details Lead Sponsor: Massachusetts General HospitalCollaborators: AmgenEmory UniversityUniversity Hospitals Cleveland Medical CenterUniversity of RochesterTreatments: Denosumab